Profile data is unavailable for this security.
About the company
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.
- Revenue in AUD (TTM)697.94k
- Net income in AUD-7.74m
- Incorporated1986
- Employees3.00
- LocationPrescient Therapeutics LtdL 4 100 Albert RdSOUTH MELBOURNE 3205AustraliaAUS
- Phone+61 39692-7222
- Fax+61 39077-9233
- Websitehttps://ptxtherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chimeric Therapeutics Ltd | 0.00 | -11.31m | 16.39m | -- | -- | 0.9948 | -- | -- | -0.027 | -0.027 | 0.00 | 0.0191 | 0.00 | -- | -- | -- | -45.96 | -- | -69.36 | -- | -- | -- | -- | -- | -- | -10.01 | 0.1596 | -- | -- | -- | -60.40 | -- | -- | -- |
Patrys Ltd | 1.70m | -5.12m | 16.46m | 15.00 | -- | 3.28 | -- | 9.71 | -0.0025 | -0.0025 | 0.0008 | 0.0024 | 0.1978 | -- | 0.5828 | -- | -59.77 | -43.96 | -68.99 | -47.06 | -- | -- | -302.26 | -230.44 | -- | -- | 0.00 | -- | -14.45 | 40.52 | -4.15 | -- | -- | -- |
Amplia Therapeutics Ltd | 4.44m | -4.50m | 16.57m | 1.00 | -- | 1.07 | -- | 3.73 | -0.0226 | -0.0226 | 0.0222 | 0.0572 | 0.2647 | -- | 2.05 | -- | -26.86 | -25.13 | -32.90 | -27.42 | -- | -- | -101.48 | -206.74 | -- | -- | 0.122 | -- | 286.42 | 144.81 | 27.86 | -- | -6.91 | -- |
Algorae Pharmaceuticals Ltd | 84.10k | -2.25m | 16.87m | -- | -- | 4.66 | -- | 200.64 | -0.0015 | -0.0015 | 0.00006 | 0.0022 | 0.0245 | -- | 1.79 | -- | -65.51 | -46.12 | -70.91 | -53.52 | -- | -- | -2,678.04 | -591.05 | -- | -136.75 | 0.00 | -- | 1,132.26 | -44.06 | -7.68 | -- | -- | -- |
Noxopharm Ltd | 3.90m | -12.13m | 19.29m | 1.00k | -- | 2.93 | -- | 4.94 | -0.0415 | -0.0415 | 0.0134 | 0.0225 | 0.2684 | -- | 1.64 | 3,901.84 | -83.43 | -50.96 | -94.78 | -62.98 | -- | -- | -310.82 | -191.70 | -- | -1.47 | 0.00 | -- | 11.32 | 44.02 | 19.34 | -- | -- | -- |
LBT Innovations Limited | 2.00m | -21.38m | 20.20m | 17.00 | -- | 6.42 | -- | 10.08 | -0.0428 | -0.0428 | 0.0038 | 0.002 | 0.1087 | 0.0819 | 2.25 | 117,882.40 | -115.89 | -28.85 | -131.86 | -30.99 | 94.76 | -- | -1,066.62 | -441.76 | 3.30 | -6.85 | 0.5633 | -- | -5.29 | -18.45 | -239.17 | -- | -34.63 | -- |
BPH Energy Ltd | 345.67k | 894.65k | 20.66m | 2.00k | 18.37 | 0.8882 | -- | 59.76 | 0.001 | 0.001 | 0.0004 | 0.0203 | 0.0177 | -- | 5.97 | -- | 4.58 | -6.89 | 4.78 | -7.72 | 56.39 | -- | 258.50 | -357.76 | -- | -- | 0.0043 | -- | 96.54 | 5.21 | 179.13 | -- | -- | -- |
Alterity Therapeutics Ltd | 123.46k | -12.28m | 20.98m | 11.00 | -- | 0.6361 | -- | 169.94 | -0.005 | -0.005 | 0.00005 | 0.0063 | 0.0044 | -- | 1.52 | 11,223.64 | -44.20 | -53.02 | -53.57 | -61.96 | -- | -- | -9,947.97 | -40,995.62 | -- | -- | 0.0143 | -- | 557.60 | -39.40 | -7.47 | -- | -34.88 | -- |
Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 21.78m | -- | -- | 3.24 | -- | 18.04 | -0.0162 | -0.0162 | 0.0039 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -- | -120.26 | -- | -- | -- | -357.70 | -- | -- | -21.62 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
Prescient Therapeutics Ltd | 697.94k | -7.74m | 31.00m | 3.00 | -- | 1.37 | -- | 44.42 | -0.0098 | -0.0098 | 0.0009 | 0.0281 | 0.0276 | -- | 2.32 | -- | -30.58 | -27.61 | -32.59 | -29.03 | -- | -- | -1,109.58 | -3,284.78 | -- | -412.91 | 0.00 | -- | 939.16 | 29.68 | -36.88 | -- | -- | -- |
Invion Ltd | 4.46m | -1.50m | 32.12m | 8.00 | -- | 1.80 | -- | 7.20 | -0.0002 | -0.0002 | 0.0007 | 0.0028 | 0.2345 | -- | 3.20 | -- | -7.88 | -16.93 | -8.12 | -18.13 | -- | -- | -33.60 | -51.63 | -- | -- | 0.00 | -- | 25.72 | 41.18 | 27.95 | -- | -- | -- |
Biotron Ltd | 1.65m | -4.02m | 34.29m | 4.00 | -- | 18.34 | -- | 20.84 | -0.0045 | -0.0045 | 0.0018 | 0.0021 | 0.3587 | -- | -- | -- | -87.73 | -64.30 | -103.46 | -74.43 | -156.30 | -108.03 | -244.54 | -231.62 | -- | -- | 0.0148 | -- | -8.16 | -2.48 | -25.59 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
DFA Australia Ltd.as of 31 May 2023 | 57.23k | 0.01% |
Dimensional Fund Advisors LPas of 30 Apr 2024 | 0.00 | 0.00% |